25-Year Mortality Trends of Hepatorenal Syndrome Vs Portal Hypertension in Older U.S. Adults with Liver Diseases: A CDC WONDER and “ARIMA Based” Analysis
25-летние тенденции смертности при гепаторенальном синдроме и портальной гипертензии у пожилых жителей США с заболеваниями печени: анализ на основе CDC WONDER и ARIMA
2026-02-13
SCID: 54.1/5hj9xyet
Discuss with AI
ARIMA forecastingCDC WONDERHepatorenal syndromeJoinpoint regressionPortal hypertension
Figures from the paper
Abstract (AI)
Abstract Introduction: As of 2019, liver cirrhosis has been ranked as the 11th leading cause of death in the U.S. Despite medical advances and available therapies, overall survival outcomes remain limited for hepatorenal syndrome (HRS) and portal hypertension (PH) have remain poor. This study seeks to evaluate the comparative disparities among liver disease patients with HRS or PH. Methodology: Mortality data from the CDC WONDER database (1999–2023) was retrieved for individuals aged ≥55 years with liver disease (ICD-10 K70–K76), focusing on HRS (K76.7) and PH (K76.6) as the contributing causes of death. Joinpoint regression analysis (JPR) was used to estimate Annual Percent Change (APC) with 95% confidence intervals (CI), stratified by age, sex, race/ethnicity, U.S. Census regions, and 2013 urbanization framework. Autoregressive Integrated Moving Average ARIMA: (0,2,1) approach was used to predict AAMRs up to 2035 along with their 95% confidence intervals. We applied Ljung-Box test to validate the model’s efficacy. A threshold for statistical significance was set at <0.05. Results: From 1999–2023, there were 14,104 PH-related deaths (AAMR: 0.69) and 47,139 HRS-related deaths (AAMR: 2.35). AAMRs for HRS group and PH group are projected to reach 3.58 (95% CI: 1.48-5.67; Ljung-Box test p-value = 0.948) and 1.63 (95% CI: 0.44-2.81; Ljung-Box test p-value = 0.155) up to 2035, respectively. In HRS, males (2007-2023) and non-Hispanics (2018-2021) showed significant upward trends in mortality , with APC of 2.09 (95% CI: 1.58-2.78; p=0.001) and 7.80 (95% CI: 1.81-9.67; p=0.01), respectively. Among those with portal hypertension, females (2010-2023) and Hispanics (2009-2021) displayed significant increases in mortality trends with APC of 7.07 (95% CI: 5.22-10.88; p=0.001) and 5.78 (95% CI: 0.43-11.60; p=0.04), respectively. Whites exhibited significant rising trends in mortality from 2008-2023 with APC of 3.28 (95% CI: 2.85-3.84; p=0.001) in HRS group. Census Region 4: West showed the highest mean AAMRs of 2.81 and 0.76 in HRS and PH group, respectively. Alaska displayed the highest AAMR of 4.2 in HRS group while North Dakota stood highest in PH group with AAMR of 1.4. Conclusion: Our study reported notable disparities , particularly the substantial rise s in APCs of Males and non-Hispanics in HRS group and females and Hispanics in PH- group, highlighting the distinct mortality patterns associated with these conditions. Furthermore, the rising AAMRs predicted by ARIMA suggest the need for targeted interventions and subtle healthcare policies.
Key Findings
1
ARIMA forecasts project HRS and portal hypertension AAMRs to increase by 2035 to 3.58 and 1.63, respectively.
2
From 1999–2023, liver disease patients had 47,139 HRS-related deaths versus 14,104 portal-hypertension-related deaths among U.S. adults aged ≥55 years.
3
HRS mortality increased significantly among males from 2007–2023 and non-Hispanics from 2018–2021, with APCs of 2.09 and 7.80, respectively.
4
HRS mortality was substantially higher than portal hypertension mortality, with AAMRs of 2.35 and 0.69, respectively.
5
Portal hypertension mortality increased significantly among females from 2010–2023 and Hispanics from 2009–2021, with APCs of 7.07 and 5.78, respectively.
6
White individuals experienced a significant rise in HRS mortality from 2008–2023, with an APC of 3.28.
Research Object
Older U.S. adults aged ≥55 years with liver diseases (ICD-10 K70–K76), including hepatorenal syndrome and portal hypertension
Research Subject
Long-term and projected mortality trends, disparities, and subgroup-specific variation for hepatorenal syndrome versus portal hypertension from 1999 to 2035
Publication Details
Publication Date
2026-02-13
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest